Tamanho Do Mercado De Testes Point-Of-Care (Poct) Da áfrica Do Sul E Da Europa Até 2030

South Africa And Europe Poct Market

Tamanho do mercado em biliões de dólares

CAGR : 9.30 %

Período de previsão	2023 –2030
Tamanho do mercado (ano base )	USD 8,565.13 Million
Tamanho do mercado ( Ano de previsão)	USD 17,289.45 Million
CAGR	9.30 %
Principais participantes do mercado	Manequim1 Manequim2 Manequim3 Manequim4 Manequim5 Pedido de desbloqueio

>Mercado de testes no local de atendimento (POCT) da África do Sul e da Europa, por tipo de produto (produtos de monitorização da glicose, produtos de teste de doenças infeciosas, produtos de monitorização cardiometabólica, produtos de teste de gravidez e fertilidade, produtos de teste de hematologia, produtos de monitorização da coagulação, medicamentos de - Produtos de teste de abuso (DOA), produtos de teste de urinálise, produtos de teste de colesterol, produtos de teste de marcadores de tumor/cancro, produtos de teste oculto fecal e outros), aplicação (glicose no sangue, monitorização cardíaca, coagulação hematológica, análise de sangue total, monitorização de sinais vitais , monitorização não invasiva de Spo2, monitorização não invasiva de Pco2, transfusão de sangue e outros), modo de prescrição (testes baseados na prescrição e testes de balcão), plataforma (ensaios de fluxo lateral/testes de imunocromatografia, varetas, diagnóstico molecular , imunoensaios, Microfluídica , Ensaio de Química Clínica, Hematologia e Outros), Utilizador Final (Clínicas, Home Care, Hospitais, Laboratórios , Centros de Cirurgia Ambulatória e Outros), Canal de Distribuição (Concurso Directo, Vendas a Retalho, Vendas Online e Outros) - Tendências do Sector e Previsão para 2030.

Análise e insights de mercado de testes no ponto de atendimento (POCT) da África do Sul e da Europa

Um dos principais factores que impulsionam o crescimento do mercado de testes no local de atendimento (POCT) da África do Sul e da Europa é a crescente prevalência de várias doenças crónicas e infecciosas. A crescente consciencialização sobre os produtos de teste no local de atendimento leva à expansão do mercado. O mercado é também influenciado pela intensa concorrência entre os participantes do mercado. No entanto, o elevado custo associado aos produtos POCT pode atuar como um fator restritivo para o mercado no período de previsão.

Por outro lado, a crescente consciencialização e o financiamento governamental funcionam como oportunidades para o crescimento do mercado. No entanto, a falta de alinhamento com os resultados dos testes obtidos em laboratórios pode criar desafios para o mercado de testes no local de atendimento (POCT) da África do Sul e da Europa.

Espera-se que o mercado de testes no local de atendimento (POCT) da África do Sul e da Europa ganhe crescimento de mercado no período de previsão de 2023 a 2030. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 9,3% no período de previsão.

Métrica de reporte	Detalhes
Período de previsão	2023 a 2030
Ano base	2022
Anos históricos	2021 personalizável (2015-2020)
Unidades Quantitativas	Receita em milhões de dólares
Segmentos cobertos	Tipo de produto (produtos de monitorização da glicose, produtos de teste de doenças infeciosas, produtos de monitorização cardiometabólica, produtos de teste de gravidez e fertilidade, produtos de teste hematológico, produtos de monitorização da coagulação, produtos de teste de drogas de abuso (DOA ), produtos de teste de urinálise, produtos de teste de colesterol, tumor / Produtos para teste de marcadores de cancro, produtos para teste oculto fecal e outros), aplicação (glicemia, monitorização cardíaca, coagulação hematológica, análise de sangue total, monitorização de sinais vitais, monitorização não invasiva de Spo2, monitorização não invasiva de PCO2, transfusão de sangue e Outros), Modo de Prescrição (Testes Baseados na Prescrição e Testes de Balcão), Plataforma (Ensaios de Fluxo Lateral/Testes de Imunocromatografia, Varetas, Diagnóstico Molecular, Imunoensaios, Microfluídica, Ensaio de Química Clínica, Hematologia e Outros), Utilizador Final (Clínicas, Cuidados Domiciliários, Hospitais, Laboratórios, Centros Cirúrgicos de Ambulatório e Outros), Canal de Distribuição (Licitação Directa, Venda a Retalho, Venda Online e Outros )
Países abrangidos	África do Sul, Alemanha, França, Reino Unido, Itália, Espanha, Países Baixos, Rússia, Suíça, Turquia, Bélgica e Resto da Europa.
Participantes do mercado abrangidos	F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Werfen, Sysmex Europe SE., Danaher, Quidel Corporation, LumiraDx, BD, Abbott, Nova Biomedical, Abaxis, Trividia Health, Inc., Sekisui Diagnostics, Thermo Fisher Scientific Inc. , EKF Diagnostics, Trinity Biotech, Chembio Diagnostics, Inc., PTS Diagnostics, binx health, inc., e QuantuMDx Group Ltd., entre outros.

Definição de mercado

O mercado de testes no local de atendimento (POCT) refere-se ao mercado de testes de diagnóstico que são realizados no local do paciente ou nas suas proximidades, fornecendo resultados imediatos para a tomada de decisões clínicas. O POCT envolve a realização de exames médicos fora do ambiente laboratorial tradicional, normalmente em ambientes como hospitais, clínicas, centros de atendimento ambulatório, consultórios médicos e até mesmo nas residências dos pacientes. O POCT foi concebido para proporcionar um acesso rápido e conveniente a informações de diagnóstico, permitindo aos profissionais de saúde tomar decisões imediatas sobre o tratamento, monitorizar as condições dos doentes e melhorar os cuidados gerais aos doentes. Os testes realizados no POCT abrangem uma vasta gama de disciplinas médicas, incluindo doenças infeciosas, saúde cardiovascular, controlo da diabetes, gravidez e fertilidade, oncologia e hematologia.

Dinâmica do mercado de testes no ponto de atendimento (POCT)

Esta secção trata da compreensão dos impulsionadores do mercado, das vantagens, das restrições e dos desafios. Tudo isto é discutido em detalhe abaixo:

Motoristas

Aumento da prevalência de doenças infeciosas e crónicas

A prevalência de doenças infecciosas e crónicas, como o cancro, a diabetes e as doenças cardiovasculares, está a aumentar rapidamente em toda a Europa. Segundo a Organização Mundial de Saúde (OMS), a contribuição das doenças crónicas foi de cerca de 60%, o que foi responsável pelo número de mortes. Na Europa, a principal razão por detrás do número crescente de doenças crónicas é o aumento contínuo do número de população geriátrica. Estas taxas crescentes de doenças são diretamente proporcionais ao crescimento do POCT, uma vez que são utilizados no diagnóstico de quase todas as doenças.

Assim, um grande aumento na prevalência de doenças crónicas actuará como um grande motor para o crescimento do mercado, uma vez que os dispositivos POCT podem gerir eficazmente a doença e proporcionar um melhor conforto e tratamento para monitorização sempre que necessário.

Melhor taxa de pesquisa de diagnóstico

A melhoria dos profissionais de saúde e as sessões regulares de formação dos profissionais que realizam exames têm contribuído para a melhoria das taxas de diagnóstico na região, o que inclui um aumento no sucesso do diagnóstico de doenças crónicas como o cancro, as doenças cardiovasculares, a diabetes tipo 2, entre outras.

Foi introduzida uma metodologia que inclui a cobertura da gestão, o tempo despendido pelo profissional para o diagnóstico e as atividades de avaliação para apoiar o processo POCT, que ajudará a melhorar a taxa de precisão da informação e auxiliará na tomada de melhores decisões em termos de diagnóstico. Assim, os esforços dos profissionais de saúde e de TI, a melhoria da formação dos profissionais de saúde, a mudança no sistema de prestação de cuidados aos doentes e a melhoria da taxa de procura de diagnóstico na região estão a conduzir ao crescimento do mercado.

Procura por dispositivos de monitorização de glicose vestíveis ou portáteis

Devido ao aumento da prevalência da diabetes entre os doentes, hoje em dia, os glicosímetros estão a tornar-se essenciais para a sua sobrevivência, uma vez que ajudam na determinação do nível de glicose. De fácil adesão, o POCT tem proporcionado conforto aos pacientes, pois podem detetar as suas condições de saúde através da verificação através do aparelho que os ajudará a prevenir problemas de saúde indesejados.

Assim, o lançamento de novos dispositivos de cuidado para monitorização de glicose wearable e portátil estará a impulsionar o crescimento do mercado.

Oportunidades

Iniciativas estratégicas dos players do mercado

O aumento da prevalência de doenças crónicas e infeciosas na Europa exige kits e soluções POCT novos e avançados com melhores taxas de eficácia e tempo de ciclo reduzido devido ao aumento da população geriátrica e também para melhorar a gestão e diagnóstico dos cuidados de saúde para um desempenho de qualidade. Os principais líderes de mercado estão empenhados em satisfazer integralmente as exigências dos profissionais de saúde e em dedicar o seu tempo à investigação para produzir melhores produtos, kits e reagentes.

Por exemplo,

Em maio de 2020, a Roche adquiriu a Stratos Genomics, uma empresa start-up na fase inicial da indústria de tecnologia de sequenciação, para avançar no desenvolvimento do seu sequenciador nanoporo que combina componentes eletrónicos e biológicos para sequenciar ADN para testes de diagnóstico clínico rápidos, adaptáveis. e acessíveis.

Consequentemente, estas iniciativas estratégicas dos players do mercado estão a funcionar como uma oportunidade que os ajuda a impulsionar o crescimento do mercado.

Aumento da Sensibilização e Financiamento Governamental

O governo, as federações e os principais intervenientes no mercado estão envolvidos na divulgação da sociedade nos países em desenvolvimento. Estas iniciativas dos intervenientes e do governo estão a ajudar os utilizadores a alcançar e a tirar partido das políticas feitas para os países de baixo rendimento e em desenvolvimento e a consciencializá-los sobre as doenças que são evitáveis se diagnosticadas precocemente. O crescimento do POCT nos hospitais e nas urgências é já fortemente incentivado pelas iniciativas governamentais e pela prevalência de doenças médicas urgentes.

Restrições/Desafios

Falta de precisão com os produtos POCT

A precisão de um POCT depende da qualidade do próprio teste. Alguns dispositivos POCT podem ter menor sensibilidade ou especificidade em comparação com os testes laboratoriais. É crucial utilizar dispositivos POCT validados e de alta qualidade para garantir resultados precisos. Algumas condições médicas ou exames específicos podem ter limitações inerentes em termos de precisão, independentemente de serem realizados em laboratório ou no local de atendimento. É importante estar ciente das limitações e possíveis fontes de erro associadas a dispositivos ou testes POCT específicos. No campo do POCT, os erros pré-analíticos são bastante comuns. Como resultado, estas circunstâncias limitam o desenvolvimento de novos produtos que dificultam a expansão do mercado, levando à recolha do produto e é realizado para remoção permanente.

Elevado custo do produto POCT

O elevado custo dos produtos POCT, incluindo dispositivos de teste, cartuchos e descartáveis, pode tornar um desafio financeiro para os prestadores de cuidados de saúde, especialmente para clínicas e instalações mais pequenas, a adopção e implementação de programas POCT. O investimento inicial necessário para adquirir o equipamento necessário e manter o fornecimento de consumíveis pode ser uma barreira significativa. O elevado custo dos produtos POCT também pode afetar indiretamente os doentes. Se o custo do POCT for transferido para os pacientes, poderá tornar os testes inacessíveis para alguns indivíduos, especialmente aqueles sem cobertura de seguro ou com franquias elevadas. Isto pode dificultar a adoção e utilização do POCT, uma vez que os doentes podem optar por métodos de teste alternativos ou renunciar completamente ao teste.

Desenvolvimentos recentes

Em abril de 2022, a Sysmex Europe SE lançou os dispositivos de teste no local de atendimento no 24º Congresso Europeu de Química Clínica e Medicina Laboratorial da IFCC-EFLM, em Munique. O lançamento do produto resultou no aumento da parceria com players do mercado para alavancagem e distribuição de dispositivos POCT e na adição de um novo produto no portfólio de produtos, resultando num aumento de receitas.
Em abril de 2021, a Danaher anunciou que cientistas de renome se juntariam a um novo conselho consultivo científico para apoiar o desenvolvimento de novas tecnologias e trazer perspetivas únicas para as tendências científicas e tecnológicas rapidamente emergentes que impactam a Danaher. Isto ajudou a empresa a diversificar o seu portefólio de segmentos.

Âmbito de mercado do Point-of-Care-Testing (POCT) da África do Sul e da Europa

O mercado de testes no local de atendimento (POCT) da África do Sul e da Europa está segmentado em seis segmentos notáveis com base no tipo de produto, aplicação, modo de prescrição, plataforma, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar os escassos segmentos de crescimento nas indústrias e a fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para tomar decisões estratégicas para identificar as principais aplicações do mercado.

Tipo de produto

Produtos de monitorização de glicose
Produtos para testes de doenças infeciosas
Produtos de monitorização cardiometabólica
Produtos para testes de gravidez e fertilidade
Produtos para testes hematológicos
Produtos de monitorização da coagulação
Produtos de teste de drogas de abuso (DOA)
Produtos para teste de urinálise
Produtos para o teste de colesterol
Produtos para teste de marcadores de tumor/cancro
Produtos para testes ocultos nas fezes
Outros

Com base no tipo de produto, o mercado de testes no local de atendimento (POCT) da África do Sul e da Europa está segmentado em produtos de monitorização da glicose, produtos de teste de doenças infeciosas, produtos de monitorização cardiometabólica, produtos de teste de gravidez e fertilidade, produtos de teste de hematologia, produtos de monitorização da coagulação, produtos para testes de drogas de abuso (DOA), produtos para testes de urinálise, produtos para testes de colesterol, produtos para testes de marcadores de tumor/cancro, produtos para testes de ocultismo fecal e outros.

Aplicação

Glicose no sangue
Monitorização Cardíaca
Hematologia
Coagulação
Análise de sangue total
Monitorização de sinais vitais
Monitorização não invasiva de Spo2
Monitorização Não Invasiva de Pco2
Transfusão de Sangue
Outros

Com base na aplicação, o mercado de testes no local de atendimento (POCT) da África do Sul e da Europa está segmentado em glicemia, monitorização cardíaca, hematologia, coagulação, análise de sangue total, monitorização de sinais vitais, monitorização não invasiva de Spo2 , não- monitorização invasiva da Pco2, transfusão de sangue e outros.

Modo de prescrição

Testes baseados na prescrição
Teste de balcão

Com base no modo de prescrição, o mercado de testes no local de atendimento (POCT) da África do Sul e da Europa está segmentado em testes baseados em prescrição e testes de balcão.

Plataforma

Ensaios de fluxo lateral/testes de imunocromatografia
Varetas
Diagnóstico Molecular
Imunoensaios
Microfluídica
Ensaio de Química Clínica
Hematologia
Outros

Com base na plataforma, o mercado de testes no local de atendimento (POCT) da África do Sul e da Europa está segmentado em ensaios de fluxo lateral/testes de imunocromatografia, varetas, diagnóstico molecular, imunoensaios, microfluídica, ensaio de química clínica, hematologia , entre outros.

Utilizador final

Clínicas
Cuidados Domiciliários
Hospitais
Laboratórios
Centros de Cirurgia Ambulatória
Outros

Com base no utilizador final, o mercado de testes no local de atendimento (POCT) da África do Sul e da Europa está segmentado em clínicas, cuidados domiciliários, hospitais, laboratórios, centros de cirurgia ambulatória, entre outros.

Canal de distribuição

Concurso Direto
Vendas no Retalho
Vendas on-line
Outros

Com base no canal de distribuição, o mercado de testes no local de atendimento (POCT) da África do Sul e da Europa está segmentado em concurso direto, vendas a retalho, vendas online, entre outros.

Análise/perspetivas regionais do mercado de testes no ponto de atendimento (POCT)

O mercado de testes no ponto de atendimento (POCT) é analisado e são fornecidos insights e tendências do tamanho do mercado por país, tipo de produto, aplicação, modo de prescrição, plataforma, utilizador final e canal de distribuição.

Os países abrangidos neste relatório são a África do Sul, a Alemanha, a França, o Reino Unido, a Itália, a Espanha, os Países Baixos, a Rússia, a Suíça, a Turquia, a Bélgica e o resto da Europa.

Espera-se que a Alemanha domine devido à crescente consciencialização e financiamento governamental para os produtos POCT, o que deverá impulsionar o mercado regional no período previsto.

A procura por diagnósticos de cancro da bexiga aumentará devido aos crescentes avanços tecnológicos. Diversas empresas estão a tomar iniciativas que levam gradualmente ao crescimento do mercado.

Análise do cenário competitivo e da quota de mercado dos testes no local de atendimento (POCT)

O panorama competitivo do mercado de testes no local de atendimento (POCT) fornece detalhes dos concorrentes. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, e domínio da aplicação. Os dados acima fornecidos estão apenas relacionados com as empresas com foco no mercado.

Alguns dos principais players que operam no mercado são a F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Werfen, Sysmex Europe SE., Danaher, Quidel Corporation, LumiraDx, BD, Abbott, Nova Biomedical, Abaxis, Trividia Health, Inc. ., Sekisui Diagnostics, Thermo Fisher Scientific Inc., EKF Diagnostics, Trinity Biotech, Chembio Diagnostics, Inc., PTS Diagnostics, binx health, inc., e QuantuMDx Group Ltd., entre outros.

SKU-70152

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Click on image to enlarge

Painel interativo de análise de dados
Painel de análise da empresa para oportunidades de elevado potencial de crescimento
Acesso de analista de pesquisa para personalização e customização. consultas
Análise da concorrência com painel interativo
Últimas notícias, atualizações e atualizações Análise de tendências
Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência

Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE

2.8 MARKET END USER COVERAGE GRID

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 STRATEGIC INITIATIVES

5 REGULATORY FRAMEWORK

5.1 REGULATORY SCENARIO IN EUROPE

5.2 REGULATORY SCENARIO IN SOUTH AFRICA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF INFECTIOUS AND CHRONIC DISEASES

6.1.2 IMPROVED DIAGNOSIS-SEEKING RATE

6.1.3 DEMAND FOR WEARABLE OR PORTABLE GLUCOSE MONITORING DEVICES

6.1.4 RISING PREFERENCE FOR HOMECARE TESTING

6.2 RESTRAINTS

6.2.1 LACK OF ACCURACY WITH POCT PRODUCTS

6.2.2 HIGH COST OF POCT PRODUCT

6.2.3 LACK OF TRAINING

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS

6.3.2 RISING AWARENESS AND GOVERNMENT FUNDING

6.4 CHALLENGES

6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES

6.4.2 IMPROPER CARE OF POCT DEVICES

7 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 GLUCOSE MONITORING PRODUCTS

7.2.1 STRIPS

7.2.2 METERS

7.2.3 LANCETS AND LANCING DEVICES

7.3 INFECTIOUS DISEASE TESTING PRODUCTS

7.3.1 INFLUENZA TESTING PRODUCTS

7.3.1.1 TRADITIONAL DIAGNOSTIC TEST

7.3.1.1.1 RAPID INFLUENZA DIAGNOSTIC TEST (RIDT)

7.3.1.1.2 DIRECT FLUORESCENT ANTIBODY TEST (DFAT)

7.3.1.1.3 VIRAL CULTURE

7.3.1.1.4 SEROLOGICAL ASSAY

7.3.1.2 MOLECULAR DIAGNOSTIC ASSAY

7.3.1.2.1 RT-PCR

7.3.1.2.2 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP)

7.3.1.2.3 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TEST (NASBAT)

7.3.1.2.4 SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA)

7.3.2 HIV TESTING PRODUCTS

7.3.2.1 TESTING EQUIPMENT

7.3.2.2 TESTING REAGENT

7.3.3 HEPATITIS C TESTING PRODUCTS

7.3.3.1 HCV ANTIBODY TESTS

7.3.3.2 HCV VIRAL LOAD TESTS

7.3.4 SEXUALLY TRANSMITTED DISEASES (STD) TESTING

7.3.4.1 NAAT-BASED SYSTEMS

7.3.4.2 NON–NAAT-BASED SYSTEMS

7.3.5 HEALTHCARE ASSOCIATED INFECTION (HAI) TESTING

7.3.6 RESPIRATORY INFECTION TESTING PRODUCTS

7.3.7 TROPICAL DISEASE TESTING PRODUCTS

7.3.8 COVID 19

7.3.9 OTHER INFECTIOUS DISEASE TESTING PRODUCTS

7.4 CARDIOMETABOLIC MONITORING PRODUCTS

7.4.1 CARDIAC MARKER TESTING PRODUCTS

7.4.1.1 HSTNL

7.4.1.2 BNP

7.4.1.3 D-DIMER

7.4.1.4 CK-MB

7.4.1.5 MYOGLOBIN

7.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS

7.4.2.1 CARTRIDGES

7.4.2.2 REAGENTS

7.4.3 HBA1C TESTING PRODUCTS

7.4.3.1 HBA1C TESTING INSTRUMENTS

7.4.3.2 HBA1C TESTING CONSUMABLES

7.4.4 POC ANALYZER

7.4.5 ECG DEVICES

7.4.5.1 RESTING ECG DEVICES

7.4.5.2 STRESS ECG DEVICES

7.4.5.3 HOLTER MONITORS

7.5 PREGNANCY AND FERTILITY TESTING PRODUCTS

7.5.1 PREGNANCY TESTING PRODUCTS

7.5.1.1 STRIPS/ DIP STICKS AND CARDS

7.5.1.2 MID STREAM DEVICES

7.5.1.3 CASSETTES

7.5.1.4 DIGITAL DEVICES

7.5.1.5 LINE-INDICATOR DEVICES

7.5.2 FERTILITY TESTING PRODUCTS

7.5.2.1 HUMAN CHORIONIC GONADOTROPIN (HCG) URINE TEST

7.5.2.2 FSH URINE TEST

7.5.2.3 LUTEINIZING HORMONE (LH) URINE TEST

7.6 HAEMATOLOGY TESTING PRODUCTS

7.7 COAGULATION MONITORING PRODUCTS

7.7.1 ANTICOAGULATION MONITORING DEVICES

7.7.2 PLATELET FUNCTION MONITORING DEVICES

7.7.3 VISCOELASTIC COAGULATION MONITORING DEVICES

7.8 DRUG-OF-ABUSE (DOA) TESTING PRODUCTS

7.8.1 DOA ANALYZERS

7.8.1.1 IMMUNOASSAYS

7.8.1.2 CHROMATOGRAPHIC DEVICES

7.8.1.3 BREATH ANALYZERS

7.8.2 RAPID TESTING DEVICES

7.8.2.1 URINE TESTING DEVICES

7.8.2.2 ORAL FLUID TESTING DEVICES

7.9 URINALYSIS TESTING PRODUCTS

7.9.1 POC URINE STRIP SELF-TESTING

7.9.2 POC URINE TEST STRIP PROFESSIONAL TESTING

7.1 CHOLESTEROL TESTING PRODUCTS

7.10.1 INSTRUMENTS

7.10.1.1 TABLE-TOP ANALYZERS

7.10.1.2 HAND-HELD ANALYZERS

7.10.2 TESTING KITS

7.11 TUMOR/CANCER MARKER TESTING PRODUCTS

7.12 FECAL OCCULT TESTING PRODUCTS

7.12.1 GUAIAC FOB STOOL TEST

7.12.2 IMMUNO-FOB AGGLUTINATION TEST

7.12.3 LATERAL FLOW IMMUNO-FOB TEST

7.12.4 IMMUNO-FOB ELISA TEST

7.13 OTHERS

8 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 BLOOD GLUCOSE

8.3 CARDIAC MONITORING

8.4 HAEMATOLOGY

8.5 COAGULATION

8.6 WHOLE BLOOD ANALYSIS

8.7 VITAL SIGN MONITORING

8.8 NON- INVASIVE SPO2 MONITORING

8.9 NON- INVASIVE PCO2 MONITORING

8.1 BLOOD TRANSFUSION

8.11 OTHERS

9 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE

9.1 OVERVIEW

9.2 PRESCRIPTION-BASED TESTING

9.3 OVER THE COUNTER TESTING

10 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM

10.1 OVERVIEW

10.2 LATERAL FLOW ASSAYS /IMMUNOCHROMATOGRAPHY TESTS

10.3 DIPSTICKS

10.4 MOLECULAR DIAGNOSTICS

10.5 IMMUNOASSAYS

10.6 MICROFLUIDICS

10.7 CLINICAL CHEMISTRY ASSAY

10.8 HEMATOLOGY

10.9 OTHERS

11 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER

11.1 OVERVIEW

11.2 CLINICS

11.3 HOME CARE

11.4 HOSPITALS

11.5 LABORATORIES

11.6 AMBULATORY SURGERY CENTERS

11.7 OTHERS

12 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 ONLINE SALES

12.5 OTHERS

13 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET

13.1 EUROPE

13.1.1 GERMANY

13.1.2 U.K.

13.1.3 FRANCE

13.1.4 SPAIN

13.1.5 ITALY

13.1.6 RUSSIA

13.1.7 NETHERLANDS

13.1.8 SWITZERLAND

13.1.9 TURKEY

13.1.10 BELGIUM

13.1.11 REST OF EUROPE

13.2 SOUTH AFRICA

14 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: EUROPE

14.2 COMPANY SHARE ANALYSIS: SOUTH AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 F HOFFMANN-LA ROCHE LTD

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 PRODUCT PORTFOLIO

16.1.4 RECENT DEVELOPMENTS

16.2 SIEMENS HEALTHCARE GMBH

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 PRODUCT PORTFOLIO

16.2.4 RECENT DEVELOPMENTS

16.3 WERFEN

16.3.1 1.3.1 COMPANY SNAPSHOT

16.3.2 PRODUCT PORTFOLIO

16.3.3 RECENT DEVELOPMENT

16.4 SYSMEX EUROPE SE.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENT

16.5 DANAHER

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 ABAXIS

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 ABBOTT

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENTS

16.8 BD

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

16.9 BINX HEALTH, INC.

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENTS

16.1 CHEMBIO DIAGNOSTICS SYSTEMS, INC

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENTS

16.11 EKF DIAGNOSTICS

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENTS

16.12 LUMIRAXDX

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENTS

16.13 NOVA BIOMEDICAL

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 PTS DIAGNOSTICS

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENTS

16.15 QUANTUMDX GROUP LTD.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 QUIDEL CORPORATION

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENTS

16.17 SEKISUI DIAGNOSTICS

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT

16.18 THERMO FISHER SCIENTIFIC INC.

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENTS

16.19 TRINITY BIOTECH

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENTS

16.2 TRIVIDIA HEALTH, INC.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

Lista de Tabela

TABLE 1 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 SOUTH AFRICA AND EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 3 SOUTH AFRICA AND EUROPE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 SOUTH AFRICA AND EUROPE INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 5 SOUTH AFRICA AND EUROPE TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 SOUTH AFRICA AND EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 SOUTH AFRICA AND EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 SOUTH AFRICA AND EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 9 SOUTH AFRICA AND EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 10 SOUTH AFRICA AND EUROPE CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 11 SOUTH AFRICA AND EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 12 SOUTH AFRICA AND EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 13 SOUTH AFRICA AND EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 14 SOUTH AFRICA AND EUROPE ECG DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 15 SOUTH AFRICA AND EUROPE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 16 SOUTH AFRICA AND EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 17 SOUTH AFRICA AND EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 18 SOUTH AFRICA AND EUROPE COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 19 SOUTH AFRICA AND EUROPE DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 20 SOUTH AFRICA AND EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 21 SOUTH AFRICA AND EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 22 SOUTH AFRICA AND EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 23 SOUTH AFRICA AND EUROPE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 24 SOUTH AFRICA AND EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 25 SOUTH AFRICA AND EUROPE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 26 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 27 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 28 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 29 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 30 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 31 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 32 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 33 EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 34 EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 35 EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 36 EUROPE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 37 EUROPE INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 38 EUROPE TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 39 EUROPE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 40 EUROPE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 41 EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 42 EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 43 EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 44 EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 45 EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 46 EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 47 EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 48 EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 49 EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 50 EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 51 EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 52 EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 53 EUROPE CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 56 EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 57 EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 58 EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 59 EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 60 EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 61 EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 62 EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 63 EUROPE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 64 EUROPE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 65 EUROPE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 66 EUROPE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 67 EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 68 EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 69 EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 70 EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 72 EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 73 EUROPE COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 74 EUROPE DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 75 EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 76 EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 77 EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 78 EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 79 EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 80 EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 81 EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 82 EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 83 EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 84 EUROPE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 85 EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 86 EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 87 EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 88 EUROPE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 89 EUROPE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 90 EUROPE FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 91 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 92 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 93 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 94 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 95 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 96 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 GERMANY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 98 GERMANY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 99 GERMANY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 100 GERMANY INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 101 GERMANY INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 102 GERMANY TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 103 GERMANY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 104 GERMANY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 105 GERMANY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 106 GERMANY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 107 GERMANY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 108 GERMANY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 109 GERMANY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 110 GERMANY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 111 GERMANY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 112 GERMANY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 113 GERMANY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 114 GERMANY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 115 GERMANY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 116 GERMANY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 117 GERMANY CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 118 GERMANY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 119 GERMANY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 120 GERMANY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 121 GERMANY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 122 GERMANY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 123 GERMANY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 124 GERMANY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 125 GERMANY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 126 GERMANY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 127 GERMANY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 128 GERMANY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 129 GERMANY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 130 GERMANY PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 131 GERMANY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 132 GERMANY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 133 GERMANY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 134 GERMANY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 135 GERMANY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 136 GERMANY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 137 GERMANY COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 138 GERMANY DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 139 GERMANY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 140 GERMANY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 141 GERMANY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 142 GERMANY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 143 GERMANY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 144 GERMANY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 145 GERMANY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 146 GERMANY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 147 GERMANY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 148 GERMANY CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 149 GERMANY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 150 GERMANY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 151 GERMANY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 152 GERMANY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 153 GERMANY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 154 GERMANY FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 155 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 156 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 157 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 158 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 159 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 160 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 161 U.K. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 162 U.K. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 163 U.K. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 164 U.K. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 165 U.K. INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 166 U.K. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 167 U.K. TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 168 U.K. TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 169 U.K. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 170 U.K. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 171 U.K. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 172 U.K. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 173 U.K. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 174 U.K. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 175 U.K. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 176 U.K. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 177 U.K. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 178 U.K. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 179 U.K. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 180 U.K. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 181 U.K. CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 182 U.K. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 183 U.K. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 184 U.K. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 185 U.K. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 186 U.K. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 187 U.K. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 188 U.K. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 189 U.K. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 190 U.K. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 191 U.K. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 192 U.K. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 193 U.K. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 194 U.K. PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 195 U.K. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 196 U.K. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 197 U.K. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 198 U.K. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 199 U.K. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 200 U.K. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 201 U.K. COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 202 U.K. DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 203 U.K. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 204 U.K. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 205 U.K. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 206 U.K. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 207 U.K. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 208 U.K. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 209 U.K. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 210 U.K. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 211 U.K. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 212 U.K. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 213 U.K. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 214 U.K. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 215 U.K. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 216 U.K. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 217 U.K. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 218 U.K. FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 219 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 220 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 221 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 222 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 223 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 224 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 225 FRANCE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 226 FRANCE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 227 FRANCE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 228 FRANCE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 229 FRANCE INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 230 FRANCE TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 231 FRANCE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 232 FRANCE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 233 FRANCE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 234 FRANCE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 235 FRANCE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 236 FRANCE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 237 FRANCE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 238 FRANCE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 239 FRANCE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 240 FRANCE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 241 FRANCE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 242 FRANCE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 243 FRANCE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 244 FRANCE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 245 FRANCE CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 246 FRANCE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 247 FRANCE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 248 FRANCE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 249 FRANCE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 250 FRANCE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 251 FRANCE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 252 FRANCE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 253 FRANCE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 254 FRANCE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 255 FRANCE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 256 FRANCE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 257 FRANCE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 258 FRANCE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 259 FRANCE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 260 FRANCE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 261 FRANCE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 262 FRANCE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 263 FRANCE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 264 FRANCE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 265 FRANCE COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 266 FRANCE DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 267 FRANCE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 268 FRANCE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 269 FRANCE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 270 FRANCE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 271 FRANCE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 272 FRANCE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 273 FRANCE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 274 FRANCE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 275 FRANCE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 276 FRANCE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 277 FRANCE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 278 FRANCE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 279 FRANCE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 280 FRANCE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 281 FRANCE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 282 FRANCE FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 283 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 284 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 285 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 286 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 287 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 288 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 289 SPAIN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 290 SPAIN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 291 SPAIN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 292 SPAIN INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 293 SPAIN INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 294 SPAIN TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 295 SPAIN TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 296 SPAIN TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 297 SPAIN MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 298 SPAIN MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 299 SPAIN MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 300 SPAIN HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 301 SPAIN HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 302 SPAIN HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 303 SPAIN HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 304 SPAIN HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 305 SPAIN HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 306 SPAIN SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 307 SPAIN SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 308 SPAIN SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 309 SPAIN CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 310 SPAIN CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 311 SPAIN CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 312 SPAIN CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 313 SPAIN BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 314 SPAIN BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 315 SPAIN BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 316 SPAIN HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 317 SPAIN HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 318 SPAIN HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 319 SPAIN ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 320 SPAIN ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 321 SPAIN ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 322 SPAIN PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 323 SPAIN PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 324 SPAIN PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 325 SPAIN PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 326 SPAIN FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 327 SPAIN FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 328 SPAIN FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 329 SPAIN COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 330 SPAIN DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 331 SPAIN DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 332 SPAIN DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 333 SPAIN DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 334 SPAIN RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 335 SPAIN RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 336 SPAIN RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 337 SPAIN URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 338 SPAIN URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 339 SPAIN URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 340 SPAIN CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 341 SPAIN INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 342 SPAIN INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 343 SPAIN INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 344 SPAIN FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 345 SPAIN FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 346 SPAIN FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 347 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 348 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 349 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 350 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 351 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 352 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 353 ITALY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 354 ITALY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 355 ITALY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 356 ITALY INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 357 ITALY INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 358 ITALY TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 359 ITALY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 360 ITALY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 361 ITALY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 362 ITALY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 363 ITALY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 364 ITALY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 365 ITALY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 366 ITALY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 367 ITALY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 368 ITALY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 369 ITALY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 370 ITALY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 371 ITALY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 372 ITALY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 373 ITALY CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 374 ITALY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 375 ITALY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 376 ITALY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 377 ITALY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 378 ITALY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 379 ITALY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 380 ITALY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 381 ITALY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 382 ITALY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 383 ITALY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 384 ITALY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 385 ITALY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 386 ITALY PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 387 ITALY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 388 ITALY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 389 ITALY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 390 ITALY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 391 ITALY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 392 ITALY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 393 ITALY COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 394 ITALY DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 395 ITALY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 396 ITALY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 397 ITALY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 398 ITALY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 399 ITALY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 400 ITALY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 401 ITALY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 402 ITALY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 403 ITALY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 404 ITALY CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 405 ITALY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 406 ITALY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 407 ITALY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 408 ITALY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 409 ITALY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 410 ITALY FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 411 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 412 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 413 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 414 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 415 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 416 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 417 RUSSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 418 RUSSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 419 RUSSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 420 RUSSIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 421 RUSSIA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 422 RUSSIA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 423 RUSSIA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 424 RUSSIA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 425 RUSSIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 426 RUSSIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 427 RUSSIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 428 RUSSIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 429 RUSSIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 430 RUSSIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 431 RUSSIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 432 RUSSIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 433 RUSSIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 434 RUSSIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 435 RUSSIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 436 RUSSIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 437 RUSSIA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 438 RUSSIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 439 RUSSIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 440 RUSSIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 441 RUSSIA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 442 RUSSIA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 443 RUSSIA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 444 RUSSIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 445 RUSSIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 446 RUSSIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 447 RUSSIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 448 RUSSIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 449 RUSSIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 450 RUSSIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 451 RUSSIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 452 RUSSIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 453 RUSSIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 454 RUSSIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 455 RUSSIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 456 RUSSIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 457 RUSSIA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 458 RUSSIA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 459 RUSSIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 460 RUSSIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 461 RUSSIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 462 RUSSIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 463 RUSSIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 464 RUSSIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 465 RUSSIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 466 RUSSIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 467 RUSSIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 468 RUSSIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 469 RUSSIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 470 RUSSIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 471 RUSSIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 472 RUSSIA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 473 RUSSIA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 474 RUSSIA FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 475 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 476 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 477 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 478 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 479 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 480 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 481 NETHERLANDS GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 482 NETHERLANDS GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 483 NETHERLANDS GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 484 NETHERLANDS INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 485 NETHERLANDS INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 486 NETHERLANDS TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 487 NETHERLANDS TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 488 NETHERLANDS TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 489 NETHERLANDS MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 490 NETHERLANDS MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 491 NETHERLANDS MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 492 NETHERLANDS HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 493 NETHERLANDS HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 494 NETHERLANDS HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 495 NETHERLANDS HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 496 NETHERLANDS HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 497 NETHERLANDS HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 498 NETHERLANDS SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 499 NETHERLANDS SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 500 NETHERLANDS SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 501 NETHERLANDS CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 502 NETHERLANDS CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 503 NETHERLANDS CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 504 NETHERLANDS CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 505 NETHERLANDS BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 506 NETHERLANDS BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 507 NETHERLANDS BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 508 NETHERLANDS HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 509 NETHERLANDS HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 510 NETHERLANDS HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 511 NETHERLANDS ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 512 NETHERLANDS ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 513 NETHERLANDS ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 514 NETHERLANDS PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 515 NETHERLANDS PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 516 NETHERLANDS PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 517 NETHERLANDS PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 518 NETHERLANDS FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 519 NETHERLANDS FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 520 NETHERLANDS FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 521 NETHERLANDS COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 522 NETHERLANDS DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 523 NETHERLANDS DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 524 NETHERLANDS DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 525 NETHERLANDS DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 526 NETHERLANDS RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 527 NETHERLANDS RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 528 NETHERLANDS RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 529 NETHERLANDS URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 530 NETHERLANDS URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 531 NETHERLANDS URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 532 NETHERLANDS CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 533 NETHERLANDS INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 534 NETHERLANDS INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 535 NETHERLANDS INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 536 NETHERLANDS FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 537 NETHERLANDS FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 538 NETHERLANDS FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 539 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 540 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 541 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 542 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 543 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 544 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 545 SWITZERLAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 546 SWITZERLAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 547 SWITZERLAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 548 SWITZERLAND INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 549 SWITZERLAND INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 550 SWITZERLAND TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 551 SWITZERLAND TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 552 SWITZERLAND TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 553 SWITZERLAND MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 554 SWITZERLAND MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 555 SWITZERLAND MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 556 SWITZERLAND HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 557 SWITZERLAND HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 558 SWITZERLAND HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 559 SWITZERLAND HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 560 SWITZERLAND HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 561 SWITZERLAND HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 562 SWITZERLAND SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 563 SWITZERLAND SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 564 SWITZERLAND SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 565 SWITZERLAND CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 566 SWITZERLAND CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 567 SWITZERLAND CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 568 SWITZERLAND CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 569 SWITZERLAND BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 570 SWITZERLAND BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 571 SWITZERLAND BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 572 SWITZERLAND HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 573 SWITZERLAND HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 574 SWITZERLAND HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 575 SWITZERLAND ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 576 SWITZERLAND ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 577 SWITZERLAND ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 578 SWITZERLAND PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 579 SWITZERLAND PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 580 SWITZERLAND PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 581 SWITZERLAND PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 582 SWITZERLAND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 583 SWITZERLAND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 584 SWITZERLAND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 585 SWITZERLAND COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 586 SWITZERLAND DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 587 SWITZERLAND DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 588 SWITZERLAND DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 589 SWITZERLAND DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 590 SWITZERLAND RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 591 SWITZERLAND RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 592 SWITZERLAND RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 593 SWITZERLAND URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 594 SWITZERLAND URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 595 SWITZERLAND URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 596 SWITZERLAND CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 597 SWITZERLAND INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 598 SWITZERLAND INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 599 SWITZERLAND INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 600 SWITZERLAND FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 601 SWITZERLAND FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 602 SWITZERLAND FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 603 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 604 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 605 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 606 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 607 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 608 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 609 TURKEY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 610 TURKEY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 611 TURKEY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 612 TURKEY INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 613 TURKEY INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 614 TURKEY TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 615 TURKEY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 616 TURKEY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 617 TURKEY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 618 TURKEY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 619 TURKEY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 620 TURKEY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 621 TURKEY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 622 TURKEY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 623 TURKEY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 624 TURKEY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 625 TURKEY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 626 TURKEY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 627 TURKEY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 628 TURKEY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 629 TURKEY CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 630 TURKEY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 631 TURKEY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 632 TURKEY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 633 TURKEY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 634 TURKEY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 635 TURKEY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 636 TURKEY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 637 TURKEY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 638 TURKEY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 639 TURKEY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 640 TURKEY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 641 TURKEY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 642 TURKEY PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 643 TURKEY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 644 TURKEY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 645 TURKEY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 646 TURKEY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 647 TURKEY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 648 TURKEY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 649 TURKEY COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 650 TURKEY DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 651 TURKEY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 652 TURKEY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 653 TURKEY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 654 TURKEY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 655 TURKEY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 656 TURKEY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 657 TURKEY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 658 TURKEY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 659 TURKEY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 660 TURKEY CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 661 TURKEY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 662 TURKEY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 663 TURKEY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 664 TURKEY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 665 TURKEY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 666 TURKEY FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 667 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 668 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 669 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 670 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 671 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 672 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 673 BELGIUM GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 674 BELGIUM GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 675 BELGIUM GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 676 BELGIUM INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 677 BELGIUM INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 678 BELGIUM TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 679 BELGIUM TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 680 BELGIUM TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 681 BELGIUM MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 682 BELGIUM MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 683 BELGIUM MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 684 BELGIUM HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 685 BELGIUM HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 686 BELGIUM HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 687 BELGIUM HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 688 BELGIUM HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 689 BELGIUM HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 690 BELGIUM SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 691 BELGIUM SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 692 BELGIUM SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 693 BELGIUM CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 694 BELGIUM CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 695 BELGIUM CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 696 BELGIUM CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 697 BELGIUM BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 698 BELGIUM BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 699 BELGIUM BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 700 BELGIUM HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 701 BELGIUM HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 702 BELGIUM HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 703 BELGIUM ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 704 BELGIUM ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 705 BELGIUM ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 706 BELGIUM PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 707 BELGIUM PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 708 BELGIUM PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 709 BELGIUM PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 710 BELGIUM FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 711 BELGIUM FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 712 BELGIUM FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 713 BELGIUM COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 714 BELGIUM DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 715 BELGIUM DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 716 BELGIUM DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 717 BELGIUM DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 718 BELGIUM RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 719 BELGIUM RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 720 BELGIUM RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 721 BELGIUM URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 722 BELGIUM URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 723 BELGIUM URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 724 BELGIUM CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 725 BELGIUM INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 726 BELGIUM INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 727 BELGIUM INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 728 BELGIUM FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 729 BELGIUM FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 730 BELGIUM FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 731 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 732 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 733 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 734 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 735 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 736 REST OF EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 737 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 738 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 739 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 740 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 741 SOUTH AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 742 SOUTH AFRICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 743 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 744 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 745 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 746 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 747 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 748 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 749 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 750 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 751 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 752 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 753 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 754 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 755 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 756 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 757 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 758 SOUTH AFRICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 759 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 760 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 761 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 762 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 763 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 764 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 765 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 766 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 767 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 768 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 769 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 770 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 771 SOUTH AFRICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 772 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 773 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 774 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 775 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 776 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 777 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 778 SOUTH AFRICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 779 SOUTH AFRICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 780 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 781 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 782 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 783 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 784 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 785 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 786 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 787 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 788 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 789 SOUTH AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 790 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 791 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 792 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 793 SOUTH AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 794 SOUTH AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 795 SOUTH AFRICA FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 796 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 797 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 798 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 799 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 800 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Lista de Figura

FIGURE 1 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION

FIGURE 2 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: DATA TRIANGULATION

FIGURE 3 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: DROC ANALYSIS

FIGURE 4 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION

FIGURE 11 RISING PREVALENCE OF CHRONIC DISEASES AND RISING PATIENT INCLINATION TOWARDS POINT-OF-CARE TESTING ARE EXPECTED TO DRIVE THE GROWTH OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET FROM 2023 TO 2030

FIGURE 12 THE GLUCOSE MONITORING PRODUCTS SEGMENT, IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET

FIGURE 14 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2022

FIGURE 15 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 16 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 17 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 18 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, 2022

FIGURE 19 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 20 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 21 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 22 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2022

FIGURE 23 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2023-2030 (USD MILLION)

FIGURE 24 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, CAGR (2023-2030)

FIGURE 25 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE

FIGURE 26 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, 2022

FIGURE 27 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, 2023-2030 (USD MILLION)

FIGURE 28 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, CAGR (2023-2030)

FIGURE 29 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, LIFELINE CURVE

FIGURE 30 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, 2022

FIGURE 31 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 32 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 35 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 36 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 37 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: SNAPSHOT (2022)

FIGURE 39 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY COUNTRY (2022)

FIGURE 40 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY COUNTRY (2023 & 2030)

FIGURE 41 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY COUNTRY (2022 & 2030)

FIGURE 42 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE (2023-2030)

FIGURE 43 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY SHARE 2022 (%)

FIGURE 44 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY SHARE 2022 (%)

View Detailed Information

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

How Big is the South Africa and Europe point-of-care-testing POCT market ?

South Africa and Europe point-of-care-testing POCT market grows with a CAGR of 9.3% and will reach USD 17,289.45 million by 2030 from USD 8,565.13 million in 2022.

Which market segments are covered in the South Africa and Europe point-of-care-testing POCT market report?

South Africa and Europe point-of-care-testing (POCT) market is segmented into six notable segments based on product type, application, prescription mode, platform, end user, and distribution channel.

Who are the major players operating in the South Africa and Europe point-of-care-testing POCT market?

Some of the major players operating in the market are F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Werfen, Sysmex Europe SE., Danaher, Quidel Corporation, LumiraDx, BD, Abbott, Nova Biomedical, Abaxis, Trividia Health, Inc., Sekisui Diagnostics, Thermo Fisher Scientific Inc., EKF Diagnostics, Trinity Biotech, Chembio Diagnostics, Inc., PTS Diagnostics, binx health, inc., and QuantuMDx Group Ltd. among others.

Which countries data are covered in the South Africa and Europe point-of-care-testing POCT market report?

The countries covered in this report are South Africa, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, and the rest of Europe.

Which region will dominate the South Africa and Europe point-of-care-testing POCT market?

Germany is expected to dominate due to rising awareness and government funding for POCT products which is expected to drive the regional market in the forecasted period.

Mercado de testes de ponto de atendimento (POCT) da África do Sul e da Europa – Tendências e previsões do setor para 2030

Mercado de testes de ponto de atendimento (POCT) da África do Sul e da Europa – Tendências e previsões do setor para 2030

South Africa And Europe Poct Market

CAGR : 9.30 %

Análise e insights de mercado de testes no ponto de atendimento (POCT) da África do Sul e da Europa

Dinâmica do mercado de testes no ponto de atendimento (POCT)

Âmbito de mercado do Point-of-Care-Testing (POCT) da África do Sul e da Europa

Análise/perspetivas regionais do mercado de testes no ponto de atendimento (POCT)

Análise do cenário competitivo e da quota de mercado dos testes no local de atendimento (POCT)

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Relatórios

Informações de mercado

Apoiar

Soluções

Mercado de testes de ponto de atendimento (POCT) da África do Sul e da Europa – Tendências e previsões do setor para 2030

Mercado de testes de ponto de atendimento (POCT) da África do Sul e da Europa – Tendências e previsões do setor para 2030

South Africa And Europe Poct Market

CAGR : 9.30 %

Análise e insights de mercado de testes no ponto de atendimento (POCT) da África do Sul e da Europa

Dinâmica do mercado de testes no ponto de atendimento (POCT)

Âmbito de mercado do Point-of-Care-Testing (POCT) da África do Sul e da Europa

Análise/perspetivas regionais do mercado de testes no ponto de atendimento (POCT)

Análise do cenário competitivo e da quota de mercado dos testes no local de atendimento (POCT)

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Navegue pelas páginas relacionadas